ASCO 2026: 92% Tumor Shrinkage and 100% Disease Control in Metastatic Pancreatic Cancer with Vopimetostat + Daraxonrasib

Friends, there are numbers that make you stop and take a deep breath before you see or read them. Take a moment and think about metastatic pancreatic cancer – one…

Continue ReadingASCO 2026: 92% Tumor Shrinkage and 100% Disease Control in Metastatic Pancreatic Cancer with Vopimetostat + Daraxonrasib